Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer

Holm, Jorun; Ahangarani Farahani, Ziba; Gerke, Oke; Baun, Christina; Falch, Kirsten; Grubbe Hildebrandt, Malene

Published in:
Diagnostics

DOI:
10.3390/diagnostics10121021

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Holm, J., Ahangarani Farahani, Z., Gerke, O., Baun, C., Falch, K., & Grubbe Hildebrandt, M. (2020). Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer. Diagnostics, 10(12), [1021]. https://doi.org/10.3390/diagnostics10121021

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:
• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying this open access version.

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 14. May. 2021
Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer

Jorun Holm 1,2,3,* , Ziba Ahangarani Farahani 1,2 , Oke Gerke 1,2 , Christina Baun 1,2,3 , Kirsten Falch 1,2 and Hildebrandt Malene Grubbe 1,2,3,4

1 Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark; ziba.farahani2@rsyd.dk (Z.A.F); Oke.Gerke@rsyd.dk (O.G.); Christina.Baun@rsyd.dk (C.B.); kirsten.falch@rsyd.dk (K.F); Malene.Grubbe.Hildebrandt@rsyd.dk (M.G.H.)

2 Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical research, University of Southern Denmark, 5000 Odense, Denmark

3 Centre of Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, 5000 Odense, Denmark

4 Centre for Innovative Medical Technology (CIMT), Odense University Hospital, 5000 Odense, Denmark

* Correspondence: jorun.holm@rsyd.dk

Received: 5 November 2020; Accepted: 26 November 2020; Published: 28 November 2020

Abstract: The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans were evaluated independently by experienced nuclear medicine physicians and the results for one modality were blinded to the other. Images were visually interpreted using a 4-point assessment scale (0 = no metastases, 1 = probably no metastases, 2 = probably metastases, 3 = definite metastases). Out of 100 women, 22 (22%) were verified with distant recurrence, 18 of these had bone involvement. The proportions of agreement between readers were 93% (86.3–96.6) for bone recurrence with FDG-PET/CT and 47% (37.5–56.7) for bone recurrence with planar bone scintigraphy. The strengths of agreement between readers for diagnosing bone recurrence was ‘almost perfect’ with FDG-PET/CT and was ‘fair’ with planar bone scintigraphy according to Cohen’s kappa value of 0.82 (0.70–0.95) and 0.28 (0.18–0.39), respectively. Interrater agreement yielded improved reproducibility with FDG-PET/CT versus with bone scintigraphy when diagnosing recurrence with bone metastasis in this patient cohort.

Keywords: agreement; bone scintigraphy; breast cancer; interrater; positron emission tomography; recurrence; repeatability; reproducibility

1. Introduction

Recent international guidelines recommend minimal imaging work-up for metastatic breast cancer to include imaging of the chest and abdomen, preferably with a computed tomography (CT) scan, and of bone [1]. It mentions that positron emission tomography (PET)/CT may be used instead of CT and bone scans, but this is not stated as a recommendation. Details on how to perform the bone scan are not mentioned: e.g., bone scan with planar imaging vs. single-photon emission computed tomography (SPECT), whether hybrid CT should be included, or if the more novel fluoride-PET scan is recommended. Former studies of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) PET-CT for the diagnosis of breast cancer metastases have shown significantly higher accuracy of FDG-PET/CT than conventional imaging with contrast-enhanced CT (ceCT), ultrasound, and/or planar...
bone scintigraphy [2–16]. These studies are primarily based on retrospective accuracy studies that have methodological limitations, including lack of sufficient reference standard, lack of blinding, and limited or no interrater reliability or agreement reports. We have previously reported higher accuracy for FDG-PET/CT compared to conventional imaging of ceCT and planar bone scintigraphy for the diagnosis of distant recurrence of breast cancer in a prospective study using histopathology and follow-up as the reference standard [17]. However, we did not report on interrater agreement, and since we consider changing recommendations for the diagnostic workup for suspected metastatic breast cancer, this would affect a large group of patients, and analyses of reproducibility such as interrater agreement should be considered as recommended by the Guidelines for Reporting Reliability and Agreement Studies (GRRAS) [18]. The GRRAS guidelines were proposed to ensure how to report both reliability and agreement, suggesting a separate follow-up publication in all larger diagnostic accuracy studies. Clinical guidelines in oncology rarely mention reliability and agreement in imaging recommendations, and accuracy studies are often the basis for evaluating the level of evidence for a diagnostic modality. The GRRAS publication does not reflect on what influence reliability and agreement should play in evaluating the level of evidence for clinical guideline algorithms, but they do stress the need for rigorous studies on these matters in the future. The GRRAS guidelines were used in this brief article investigating interrater agreement between nuclear medicine experts in the data from our previous prospective study of FDG-PET/CT versus ceCT and planar bone scintigraphy in patients with clinically suspected recurrent breast cancer [17]. We aimed to investigate the interrater agreement for diagnosing bone recurrence when using FDG-PET/CT and comparing it with planar bone scintigraphy. We also investigated the interrater agreement for diagnosing distant recurrence, including extra-osseous metastases, using FDG-PET/CT.

2. Materials and Methods

The study was conducted in compliance with the Declaration of Helsinki. Permission was given from the local ethics committee (S-20110138), approved on 28th of November 2011, and informed consent was obtained from all included patients.

The imaging data comprised the scans of women with suspected recurrence of breast cancer, performed at the Department of Nuclear Medicine in a prospective study at our institution from December 2011 to September 2014 [17]. The patients underwent planar whole-body bone scintigraphy with [99Tc]-dicarboxypropane diphosphonate and FDG-PET/CT within a median period of 3 days (range 0–24). Patients with suspected breast cancer recurrence or with verified local recurrence and potential distant metastases were invited to participate. Exclusion criteria were other malignancy, age less than 18 years, pregnancy or breast-feeding, diabetes mellitus, or considered unable to cooperate. The sample size calculation was based on accuracy considerations for the main study [17]: We assumed a prevalence of recurrence of 20% and based our calculation on a total sample size of 150 patients. The duration of the inclusion period was intended to be 2 years, but because of slower-than-expected recruitment, the number of patients included after 3 years was 102. The main reason for the closure of the study was that the time allotted had been exceeded. The reference standard was biopsy along with treatment decisions and clinical follow-up (median 19 months, range 1–35 months). In the current study, interrater agreement analyses of distant recurrence were performed for the FDG-PET/CT scan, and analyses of bone recurrence were compared with planar bone scintigraphy. Details for sample size calculations and scan procedures can be seen in the main publication [17].

2.1. Image Interpretation

One-hundred scans from the two imaging modalities were evaluated independently by experienced nuclear medicine physicians from our institution. The initial ratings for the main accuracy study were done by Z.A.F. (7-year experience) for the bone scans and M.G.H. (10-year experience) for the FDG-PET/CT scans. The subsequent ratings for the interrater study were done two years later, where the bone scans were evaluated by J.H. (7-year experience) and the FDG-PET/CT scans by Z.A.F.
(9-year experience). All raters were aware of the referral text, but were blinded to each other, to any other imaging results, and other test results, e.g., the biopsy reports. Images were visually interpreted using a 4-point assessment scale: 0 = no sign of metastases, 1 = probably no metastases, 2 = probably metastases, and 3 = definite signs of metastases. Bone metastases were defined as metastases in the bone or bone marrow. Distant metastases were defined as all verified metastases other than local metastases in the operated breast and ipsilateral axilla; hence, distant metastases comprised metastases in all non-local regions, including bone metastases.

2.2. Statistical Analysis

Descriptive statistics were assessed according to data type: Continuous variables were displayed with medians and ranges, and categorical variables were characterized by frequencies that are identical with respective percentages due to a sample size of \( n = 100 \). Agreement analyses were based on proportions of agreement and Cohen’s kappa [19]. These estimates were supplemented by 95% confidence intervals (95% CIs) based on the Wilson-score method and bootstrapping techniques, respectively [20,21]. The level of significance was 5%, and the data were analyzed with Stata/MP 15 (StataCorp LP, College Station, TX 77845, USA).

3. Results

Of the 102 patients who were initially included, one changed her mind, and another was excluded due to a previous known biopsy-verified bone metastasis, leaving 100 women available for analysis. Twenty-two patients out of 100 patients (22%) were diagnosed with distant recurrence, all diagnosed by biopsy; of those, 18 were classified as having bone metastases. Details on patient characteristics and other results can be seen in the main article [17], and additionally in Table 1.

| Description                      | Descriptive Statistics |
|----------------------------------|------------------------|
| Primary site                     | Left 55                |
|                                  | Right 42               |
|                                  | Bilateral 3            |
| Type of surgery                  | Breast-conserving 59   |
|                                  | Mastectomy 41          |
| Adjuvant chemo- and/or radiotherapy | Yes 92                |
|                                  | No 8                   |
| Histology of the primary tumor   | Invasive ductal carcinoma 73 |
|                                  | Invasive lobular carcinoma 13 |
|                                  | Ductal carcinoma in situ 5 |
|                                  | Other 8                |
|                                  | Missing 1              |
| Stage of disease at diagnosis 1  | I 16                   |
|                                  | II 44                  |
|                                  | III 23                 |
|                                  | Missing 17             |
| Estrogen receptor status         | Positive 79            |
|                                  | Negative 15            |
|                                  | Missing 6              |
Table 1. Cont.

| Description                          | Positive | \( n = 37 \) |
|--------------------------------------|----------|--------------|
| Progesterone receptor status         | Negative | \( n = 57 \) |
|                                      | Missing  | \( n = 6 \)  |
|--------------------------------------|----------|--------------|
| HER-2 status                         | Positive | \( n = 13 \) |
|                                      | Negative | \( n = 81 \) |
|                                      | Missing  | \( n = 6 \)  |
|--------------------------------------|----------|--------------|
| Sentinel node procedure              | Yes      | \( n = 54 \) |
|                                      | No       | \( n = 42 \) |
|                                      | Missing  | \( n = 4 \)  |
|--------------------------------------|----------|--------------|
| Axillary dissection                  | Yes      | \( n = 69 \) |
|                                      | No       | \( n = 29 \) |
|                                      | Missing  | \( n = 2 \)  |

|                                      | Total years since treatment for primary breast cancer | 4 (0, 30) |
|--------------------------------------|-----------------------------------------------------|-----------|
| Tumor size in millimeters; missing: | Total number of lymph nodes removed; missing:       | 17 (5, 110) |
| \( n = 7 \)                         | \( n = 6 \)                                        | 14 (1, 32) |
| Number of positive lymph nodes;     |                                                     | 1 (0, 23)  |
| missing: \( n = 5 \)                |                                                     |           |

\(^1\) Stage of the disease was defined according to the Bloom–Richardson grading system.

Interrater Agreement

The proportion of agreement between readers was 80\% (95 CI: 71.1–86.7) for diagnosing distant recurrence and 93\% (95 CI: 86.3–96.6) for diagnosing bone recurrence with FDG-PET/CT. The proportion of agreement for diagnosing bone recurrence was 47\% (95 CI: 37.5–56.7) with planar bone scintigraphy. The strengths of agreement between readers with FDG-PET/CT were ‘substantial’ for diagnosing distant recurrence and ‘almost perfect’ for diagnosing bone recurrence according to Cohen’s kappa values of 0.65 (0.52–0.78) and 0.82 (0.70–0.95), respectively. The agreement between readers for diagnosing bone recurrence with planar bone scintigraphy was ‘fair’ with a Cohen’s kappa value of 0.28 (0.18–0.39). Cross tabulations of raters 1 and 2 for assessment of distant recurrence with FDG-PET/CT, bone recurrence with FDG-PET/CT, and bone recurrence with planar bone scintigraphy are shown in Table 2. Figure 1 is illustrating the interrater agreement with the interpretation of FDG-PET/CT versus the interrater non-agreement with the interpretation of the bone scintigraphy for one of the patients.

Table 2. Cross tabulations of raters 1 and 2 for assessment of distant recurrence with FDG-PET/CT, bone recurrence with FDG-PET/CT, and of rater 2 and 3 for bone recurrence with planar bone scintigraphy.

| Distant recurrence assessed with PET |
|-------------------------------------|----------|---------|---------|---------|
| Rater 1                             | Rater 2  | Total (%)|
|-------------------------------------|----------|----------|
| 0                                   | 53       | 7        | 1       | 0       |
| 1                                   | 5        | 4        | 0       | 1       |
| 2                                   | 2        | 2        | 1       | 1       |
| 3                                   | 0        | 0        | 1       | 22      |
| Total                               | 60       | 13       | 3       | 24      | 100     |
Table 2. Cont.

| Bone recurrence assessed with PET | Rater 1 | Rater 2 | Total (%) |
|----------------------------------|---------|---------|-----------|
|                                  | 0       | 1       | 2         | 3         |
| 0                                | 73      | 2       | 0         | 1         | 76        |
| 1                                | 1       | 2       | 0         | 1         | 4         |
| 2                                | 0       | 1       | 0         | 1         | 2         |
| 3                                | 0       | 0       | 0         | 18        | 18        |
| Total                            | 74      | 5       | 0         | 21        | 100       |

| Bone recurrence assessed with BS | Rater 3 | Rater 2 | Total (%) |
|---------------------------------|---------|---------|-----------|
|                                  | 0       | 1       | 2         | 3         |
| 0                                | 27      | 35      | 0         | 0         | 62        |
| 1                                | 0       | 11      | 2         | 0         | 13        |
| 2                                | 0       | 3       | 4         | 0         | 7         |
| 3                                | 1       | 1       | 11        | 5         | 18        |
| Total                            | 28      | 50      | 17        | 5         | 100       |

BS: bone scintigraphy. FDG: 2-deoxy-2-[18F]fluoro-D-glucose. PET: positron emission tomography. Scale: 0 = no sign of metastases, 1 = probably no metastases, 2 = probably metastases, 3 = definite signs of metastases.

Figure 1. Bone scintigraphy (A) and transaxial FDG-PET/CT images over the thorax (B) and pelvis (C) of a 50-year-old woman without metastases (seven months of follow-up). The raters disagreed in the interpretation of the bone scintigraphy (A). Rater 2 interpreted these with point assessment 2 (probably metastases), while rater 3 interpreted the small focus in the left side of the pelvis and the successive foci in ribs (red arrows) with point assessment 1 (probably no metastases). On FDG-PET/CT (B + C), the two raters agreed about point assessment 0 (no metastasis). The focal FDG-uptake in the ribs was interpreted as sequelae of non-malignant traumatic fractures, and no focal FDG-uptake or structural pathology was observed in the left part of the pelvis on FDG-PET/CT (red arrows).
4. Discussion

In this interrater agreement study, the proportions of agreement between readers were substantially higher with FDG-PET/CT than with planar bone scintigraphy for diagnosis of bone recurrence in breast cancer patients. Accuracy results have had the primary focus in the literature about diagnosis of recurrent breast cancer, and no previous reports of interrater agreement on recurrent breast cancer with FDG-PET/CT exist, to the best of our knowledge [11–14,17].

The strengths of this inter-rater agreement study are that it was performed prospectively, that histopathology was used as the reference standard, a short time (three days) between the imaging modalities, and interrater assessments were made by highly and rather equally experienced nuclear medicine specialists who were blinded to other test results. One of the raters (Z.A.F.) assessed both modalities, but with two years between the assessments, thus reducing the risk of a recall bias. The GRRAS guidelines suggest a clear statement of any crossing-over of raters or subjects in interrater studies to help readers decide whether the statistical analysis was appropriate. However, they do not state an optimal number of observers in interrater agreement studies.

Limitations of our study include the fact that it was performed only at a single institution, restricting generalization from our results. The three raters were employed in the same department and the agreement in readings of FDG-PET/CT may be more aligned as a result of similarity in background and training compared to a multicenter study. However, this alignment should apply to the inter-rater agreement for planar bone scintigraphy as well, which was not the case. Another limitation was that the power calculation was based on accuracy considerations for the main study alone. The sample size of 100 women is too small to extrapolate the results to other institutions or to propose alterations of clinical guidelines. We encourage more interrater studies in the future, because we find it clinically essential that the measurements of our diagnostic tools are of good quality regarding reproducible and reliability. The planar bone scintigraphy was performed without SPECT/CT, and the more novel bone modality sodium-[18F]fluoride PET/CT was not included for analysis. It could be expected that these modalities known to have better accuracy than planar bone scintigraphy would improve the interrater agreement for the bone scan, but we are not familiar with any interrater studies on bone recurrence in breast cancer performed with these modalities.

5. Conclusions

Interrater agreement was substantial for diagnosing distant recurrence with FDG-PET/CT, and it was significantly higher for FDG-PET/CT (almost perfect) than for planar bone scintigraphy (fair) when diagnosing bone recurrence. These results demonstrate an improved reproducibility of reporting FDG-PET/CT compared with planar bone scintigraphy in diagnosing bone recurrence in breast cancer patients. We suggest interrater agreement studies to become more integrated into the development of diagnostic algorithms and guidelines for diagnosing recurrent breast cancer to ensure quality in reproducibility and reliability.

Author Contributions: Conceptualization, M.G.H.; methodology, M.G.H. and O.G.; software, O.G.; validation, J.H., Z.A.F., and M.G.H.; formal analysis, J.H., Z.A.F., O.G., and M.G.H.; investigation, C.B. and K.F.; resources, M.G.H., C.B., and K.F.; data curation, O.G. and M.G.H.; writing—original draft preparation, J.H.; writing—review and editing; J.H., M.G.H., and O.G.; visualization, M.G.H.; supervision, O.G. and M.G.H.; project administration, J.H.; funding acquisition, M.G.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially supported by the Independent Research Fund Denmark (DFF–7016-00359) and the Centre of Personalized Response Monitoring in Oncology (PREMIO) at Odense University Hospital.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; André, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C.H.; Bergh, J.; et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer. Ann. Oncol/ESMO 2020, 31, 1623–1649. [CrossRef] [PubMed]

2. Aukema, T.S.; Rutgers, E.T.; Vogel, W.V.; Teertstra, H.J.; Oldenburg, H.S.; Peeters, M.V.; Wesseling, J.; Russell, N.S.; Olmos, R.V. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur. J. Surg. Oncol. 2010, 36, 387–392. [CrossRef] [PubMed]

3. Champion, L.; Brain, E.; Giraudet, A.L.; Le Stanc, E.; Wartski, M.; Edeline, V.; Madar, O.; Bellet, D.; Pecking, A.; Alberini, J.L. Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011, 117, 1621–1629. [CrossRef] [PubMed]

4. Constantinidou, A.; Martin, A.; Sharma, B. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann. Oncol. 2011, 22, 307–314. [CrossRef]

5. Dirisamer, A.; Halpern, B.S.; Flöry, D.; Wolf, F.; Beheshi, M.; Mayerhofer, M.E.; Langsteger, W. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur. J. Radiol. 2010, 73, 294–299. [CrossRef]

6. Evangelista, L.; Baretta, Z.; Vinante, L.; Bezzon, E.; De Carolis, V.; Cervino, A.R.; Gregianin, M.; Ghiotto, C.; Saladini, G.; Pomerri, F.; et al. Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: Diagnostic and prognostic implications. Q. J. Nucl. Med. Mol. Imaging 2012, 56, 375–384.

7. Evangelista, L.; Baretta, Z.; Vinante, L.; Cervino, A.R.; Gregianin, M.; Ghiotto, C.; Saladini, G.; Sotti, G. Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 2011, 38, 307–314. [CrossRef]

8. Filippi, V.; Malamitsi, J.; Vlachou, F.; Laspas, F.; Georgiou, E.; Prassopoulos, V.; Andreou, J. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl. Med. Commun. 2011, 32, 85–90. [CrossRef]

9. Fueger, B.J.; Weber, W.A.; Quon, A.; Crawford, T.L.; Allen-Auerbach, M.S.; Halpern, B.S.; Ratib, O.; Phelps, M.E.; Czerin, J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol. Imaging Biol. 2005, 7, 369–376. [CrossRef]

10. Grassetto, G.; Fornasiero, A.; Otello, D.; Bonciarelli, G.; Rossi, E.; Nashimben, O.; Minicocci, A.M.; Crepaldi, G.; Pasini, F.; Facci, E.; et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study. Eur. J. Radiol. 2011, 80, 828–833. [CrossRef]

11. Haug, A.R.; Schmidt, G.P.; Klingenstein, A.; Heinemann, V.; Stieber, P.; Prieme, M.; la Fougère, C.; Becker, C.; Hahn, K.; Tiling, R. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J. Comput. Assist. Tomogr. 2007, 31, 629–634. [CrossRef] [PubMed]

12. Mahner, S.; Schirrmacher, S.; Brenner, W.; Jenicke, L.; Habermann, C.R.; Avril, N.; Dose-Schwarz, J. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann. Oncol. 2008, 9, 1249–1254. [CrossRef] [PubMed]

13. Manohar, K.; Mittal, B.R.; Senthil, R.; Kashyap, R.; Bhattacharya, A.; Singh, G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl. Med. Commun. 2012, 33, 591–596. [CrossRef] [PubMed]

14. Murakami, R.; Kumita, S.I.; Yoshida, T.; Ishihara, K.; Kiriyama, T.; Hakozaki, K.; Yanagihara, K.; Iida, S.; Tsuchiya, S.I. FDG-PET/CT in the diagnosis of recurrent breast cancer. Acta Radiol. 2012, 53, 12–16. [CrossRef]

15. Radan, L.; Ben-Haim, S.; Bar-Shalom, R.; Guralnik, L.; Israel, O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006, 107, 2545–2551. [CrossRef]

16. Veit-Haibach, P.; Antoch, G.; Beyer, T.; Stergar, H.; Schleucher, R.; Hauth, E.A.M.; Bockisch, A. FDG-PET/CT in restaging of patients with recurrent cancer: possible impact on staging and therapy. Br. J. Radiol. 2007, 80, 508–515. [CrossRef]
17. Hildebrandt, M.G.; Gerke, O.; Baun, C.; Falch, K.; Hansen, J.A.; Farahani, Z.A.; Petersen, H.; Larsen, L.B.; Duvnjak, S.; Buskevica, I.; et al. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy. *J. Clin. Oncol.* 2016, 34, 1889–1897. [CrossRef]

18. Kottner, J.; Audigé, L.; Brorson, S.; Donner, A.; Gajewski, B.J.; Hróbjartsson, A.; Roberts, C.; Shoukri, M.; Streiner, D.L. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. *J. Clin. Epidemiol.* 2011, 64, 96–106. [CrossRef] [PubMed]

19. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. *Biometrics* 1977, 33, 159–174. [CrossRef] [PubMed]

20. Newcombe, R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. *Stat. Med.* 1998, 17, 857–872. [CrossRef]

21. Efron, B. Nonparametric Estimates of Standard Error: The Jackknife, the Bootstrap and Other Methods. *Biometrika* 1981, 68, 589–599. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).